Intravitreal aflibercept versus intravitreal ranibizumab in patients with age-related macular degeneration: a comparative effectiveness study (2024)

Smit, C. H., Wiertz-Arts, K. (2018). Intravitreal aflibercept versus intravitreal ranibizumab in patients with age-related macular degeneration: a comparative effectiveness study. Comparative Hepatology, 7(6), 561-567. https://doi.org/10.2217/cer-2017-0099

Smit, Cornelis H ; Wiertz-Arts, Karin ; van de Garde, Ewoudt Mw. / Intravitreal aflibercept versus intravitreal ranibizumab in patients with age-related macular degeneration : a comparative effectiveness study. In: Comparative Hepatology. 2018 ; Vol. 7, No. 6. pp. 561-567.

@article{204856d2c4264329ba7ab49d565a8841,

title = "Intravitreal aflibercept versus intravitreal ranibizumab in patients with age-related macular degeneration: a comparative effectiveness study",

abstract = "AIM: A hospital-wide, unselected switch of ranibizumab to aflibercept in treatment of age-related macular degeneration (AMD) allowed us to compare the clinical effectiveness of these agents.METHOD: In a single-center before-after, observational study design new AMD-patients started with aflibercept treatment in 2013-2014 were compared with a control group of AMD-patients on ranibizumab before the switch.RESULTS: The mean difference in visual acuity (in logMAR units) after 1 year was comparable (+0.012 [aflibercept, n = 37] vs +0.17 [ranibizumab, n = 30], p = 0.154). However, the aflibercept-group did receive more intravitreal injections (5.8 vs 4.7 injections, p = 0.004) and were treated longer (265.7 vs 197.7 days; p = 0.011).CONCLUSION: With no difference in clinical effectiveness, longer treatment intervals for aflibercept should be investigated.",

keywords = "age-related macular degeneration, anti-VEGF treatment, comparative effectiveness research, ranibizumab, aflibercept",

author = "Smit, {Cornelis H} and Karin Wiertz-Arts and {van de Garde}, {Ewoudt Mw}",

year = "2018",

doi = "10.2217/cer-2017-0099",

language = "English",

volume = "7",

pages = "561--567",

journal = "Comparative Hepatology",

issn = "1476-5926",

publisher = "BioMed Central",

number = "6",

}

Smit, CH, Wiertz-Arts, K 2018, 'Intravitreal aflibercept versus intravitreal ranibizumab in patients with age-related macular degeneration: a comparative effectiveness study', Comparative Hepatology, vol. 7, no. 6, pp. 561-567. https://doi.org/10.2217/cer-2017-0099

Intravitreal aflibercept versus intravitreal ranibizumab in patients with age-related macular degeneration: a comparative effectiveness study. / Smit, Cornelis H; Wiertz-Arts, Karin; van de Garde, Ewoudt Mw.
In: Comparative Hepatology, Vol. 7, No. 6, 2018, p. 561-567.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Intravitreal aflibercept versus intravitreal ranibizumab in patients with age-related macular degeneration

T2 - a comparative effectiveness study

AU - Smit, Cornelis H

AU - Wiertz-Arts, Karin

AU - van de Garde, Ewoudt Mw

PY - 2018

Y1 - 2018

N2 - AIM: A hospital-wide, unselected switch of ranibizumab to aflibercept in treatment of age-related macular degeneration (AMD) allowed us to compare the clinical effectiveness of these agents.METHOD: In a single-center before-after, observational study design new AMD-patients started with aflibercept treatment in 2013-2014 were compared with a control group of AMD-patients on ranibizumab before the switch.RESULTS: The mean difference in visual acuity (in logMAR units) after 1 year was comparable (+0.012 [aflibercept, n = 37] vs +0.17 [ranibizumab, n = 30], p = 0.154). However, the aflibercept-group did receive more intravitreal injections (5.8 vs 4.7 injections, p = 0.004) and were treated longer (265.7 vs 197.7 days; p = 0.011).CONCLUSION: With no difference in clinical effectiveness, longer treatment intervals for aflibercept should be investigated.

AB - AIM: A hospital-wide, unselected switch of ranibizumab to aflibercept in treatment of age-related macular degeneration (AMD) allowed us to compare the clinical effectiveness of these agents.METHOD: In a single-center before-after, observational study design new AMD-patients started with aflibercept treatment in 2013-2014 were compared with a control group of AMD-patients on ranibizumab before the switch.RESULTS: The mean difference in visual acuity (in logMAR units) after 1 year was comparable (+0.012 [aflibercept, n = 37] vs +0.17 [ranibizumab, n = 30], p = 0.154). However, the aflibercept-group did receive more intravitreal injections (5.8 vs 4.7 injections, p = 0.004) and were treated longer (265.7 vs 197.7 days; p = 0.011).CONCLUSION: With no difference in clinical effectiveness, longer treatment intervals for aflibercept should be investigated.

KW - age-related macular degeneration

KW - anti-VEGF treatment

KW - comparative effectiveness research

KW - ranibizumab

KW - aflibercept

U2 - 10.2217/cer-2017-0099

DO - 10.2217/cer-2017-0099

M3 - Article

C2 - 29855194

SN - 1476-5926

VL - 7

SP - 561

EP - 567

JO - Comparative Hepatology

JF - Comparative Hepatology

IS - 6

ER -

Smit CH, Wiertz-Arts K, van de Garde EM. Intravitreal aflibercept versus intravitreal ranibizumab in patients with age-related macular degeneration: a comparative effectiveness study. Comparative Hepatology. 2018;7(6):561-567. Epub 2018 Jun 1. doi: 10.2217/cer-2017-0099